Case Challenges in nAMD and DME Management: Achieving Durable Response

Activity Chair

Carl J. Danzig, MD, FASRS

Director of Vitreoretinal Services and Retina Clinical Research

Rand Eye Institute

Deerfield Beach, FL

Affiliate Assistant Professor of Clinical Biomedical Science

Charles E. Schmidt College of Medicine

Florida Atlantic University

Boca Raton, FL

Faculty

Ferhina S. Ali, MD, MPH

Assistant Professor

New York Medical College

Valhalla, NY

Jordan M. Graff, MD, FACS, FABO

Surgeon & Partner, BDP Eye Center – Retina Division

American Vision Partners (AVP) Medical Executive Team

Phoenix, AZ

Michael A. Singer, MD

Director of Clinical Research

Medical Center Ophthalmology Associates

Clinical Professor of Ophthalmology

University of Texas Health Science Center

San Antonio, TX

Overview

The management of diabetic macular edema (DME) and neovascular age-related macular degeneration (nAMD) with intravitreal anti-vascular endothelial growth factor (VEGF) therapies has provided enhanced visual outcomes for many patients. However, the high treatment burden associated with anti-VEGF therapies can lead to lack of patient adherence, resulting in suboptimal outcomes. Personalized treatment protocols using FDA-approved agents, and newer novel delivery systems, along with agents with unique mechanisms of action, have sought to address treatment burden by extending the interval between dosing of treatment while providing visual acuity gains. In this case-based CME and COPE activity, experts in the field will evaluate treatment protocols that offer increased efficacy, safety, and durability in patients with nAMD and DME, and they will provide guidance for practices and procedures that can improve patient adherence to therapeutic regimens. This program will also include the unique, audience-driven, educational platform Case Choice, where learners select 1 of 2 cases in a pair for discussion.

Agenda

6:30 PM

Registration and Dinner

7:00 PM

Introduction and Pretest

7:05 PM

Transitioning nAMD and DME Treatment in 2023: What’s New?

7:30 PM

Case Choice

You and colleagues in the audience will drive the discussion, voting on the case selection and answering polling questions regarding clinical decisions.

• Improving nAMD Treatment Adherence
• Management of Newly Diagnosed DME
• Management of Treatment-Refractory DME

8:15 PM

Posttest and Question & Answer

8:30 PM

Conclusion

Learning Objectives

Upon successful completion of this activity, participants should be better able to:

• Recognize treatment protocols that offer increased efficacy, safety, and durability in patients with nAMD and DME.
• Select the most appropriate treatment regimen in patients with nAMD and DME based upon clinical presentation, imaging, and the latest evidence on efficacy and safety.
• Incorporate practices and procedures that can improve patient adherence to nAMD and DME therapeutic regimens.

Target Audience

The intended audience for this activity is retina specialists, ophthalmologists, optometrists, and other healthcare professionals involved in the management of patients with nAMD and DME.